ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
Status:
Terminated
Trial end date:
2021-01-09
Target enrollment:
Participant gender:
Summary
Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) has caused an international outbreak of respiratory illness described as
COVID-19.
Individuals with a history of cardiovascular disease develop a more severe illness and have
higher rates of death.
Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of
infection, there are ongoing scientific discussions on whether they should be stopped or
continued in patients with COVID-19.
It is crucial to determine whether RAS blockers should be discontinued or not in patients
with COVID-19.